Search

Your search keyword '"Dargan, Paul I"' showing total 1,224 results

Search Constraints

Start Over You searched for: Author "Dargan, Paul I" Remove constraint Author: "Dargan, Paul I"
1,224 results on '"Dargan, Paul I"'

Search Results

3. Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial

5. Self-discharge during treatment for acute recreational drug toxicity: an observational study from emergency departments in seven European countries

7. Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland

11. Severity of emergency department presentations due to acute drug toxicity in Europe: a longitudinal analysis over a 6-year period (2014–2019) stratified by sex

13. Contributors

14. Clinical effects of cannabis compared to synthetic cannabinoid receptor agonists (SCRAs): a retrospective cohort study of presentations with acute toxicity to European hospitals between 2013 and 2020

15. Intravenous lipid emulsion interference in coagulation testing: an ex vivo analysis.

17. Clinical effects of cannabis compared to synthetic cannabinoid receptor agonists (SCRAs): a retrospective cohort study of presentations with acute toxicity to European hospitals between 2013 and 2020.

18. Clinical effect of ethanol co-use in patients with acute drug toxicity involving the use of central nervous system depressant recreational drugs

19. Comparison of recreational drug presentations to the emergency department in Europe, the Middle East and Northern Africa

21. Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial

22. The global burden of injury: incidence, mortality, disability-adjusted life years and time trends from the Global Burden of Disease study 2013

24. Patterns of Acute Toxicity Associated with New Psychoactive Substances

26. 44th International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT), 28–31 May 2024, Munich, Germany.

27. Artificial intelligence in clinical pharmacology: A case study and scoping review of large language models and bioweapon potential.

29. Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland

34. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016

35. Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016

36. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016

37. Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015

38. Acute Stimulant Toxicity from the Use of Ocean Burst and Lunar Wave Bath Salts: Detection of 3-Chlorophenmetrazine and the Cathinones N-ethylpentedrone and Alpha-pyrrolidinoisohexanophenone (alpha PHiP).

39. Review of European-Drug Emergencies Network (Euro-DEN) Training Package for Non-Specialist Workers to Assess Acute Recreational Drug and New Psychoactive Substance Toxicity in Night-Time Economy Environments

44. Determinants of Admission to Critical Care Following Acute Recreational Drug Toxicity: A Euro-DEN Plus Study

45. Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015

46. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015

47. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015

48. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015

49. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015

Catalog

Books, media, physical & digital resources